The billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patients

Ozempic, Wegovy, and similar drugs may deliver excellent health value, but covering them for millions of eligible patients could overwhelm insurance budgets. Researchers say better long-term support is needed and warn that low-cost compounded versions may carry serious safety risks.

Scientific signal separates durable discovery from noise — and often foreshadows policy and product.

ScienceDaily reported on this under science. RedScroll surfaces the signal with an extractive brief — not a reprint of the original article. Read the source for full reporting.